{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-008593","form_type":"8-K","ticker":"IKT","cik":"0001750149","company_name":"Inhibikase Therapeutics, Inc.","filed_at":"2024-01-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.386476+00:00","generated_at":"2026-06-06T23:21:04.081511+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Inhibikase CFO Joseph Frattaroli to retire; Garth Lees-Rolfe promoted as successor","bullets":["Joseph Frattaroli to retire as CFO effective March 31, 2024; vested stock option exercise period extended.","Garth Lees-Rolfe, current VP of Finance since Nov 2022, will become CFO upon Frattaroli's retirement.","Lees-Rolfe previously VP Finance at F-Star and spent 16 years in public practice, including at Ernst & Young.","Retirement is not due to any disagreement with the Company; transition is planned and orderly.","Compensation for Lees-Rolfe as CFO not yet determined; to be disclosed in a future 8-K amendment."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-008593","json":"https://secwatch.observer/filing/0001193125-24-008593.json","markdown":"https://secwatch.observer/filing/0001193125-24-008593.md","text":"https://secwatch.observer/filing/0001193125-24-008593.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1750149/000119312524008593/0001193125-24-008593-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1750149/000119312524008593/d125920d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T23:21:04.081511+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0f89e7cb4e","claim":"Joseph Frattaroli departed as Chief Financial Officer at Inhibikase Therapeutics, Inc..","evidence_excerpt":"Joseph Frattaroli provided notice to the Board of Directors (the “Board”) of Inhibikase Therapeutics, Inc. (the “Company”) of his intention to retire as Chief Financial Officer of the Company, effective at the end of the first quarter of 2024 or March 31, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1750149/000119312524008593/0001193125-24-008593-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"retire"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"4f3b4f3f20","claim":"Garth Lees-Rolfe was appointed as Chief Financial Officer at Inhibikase Therapeutics, Inc..","evidence_excerpt":"The Board will appoint Garth Lees-Rolfe to serve as Chief Financial Officer of the Company upon Mr. Frattaroli’s retirement and until the earliest of his removal, termination, or resignation from such office.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1750149/000119312524008593/0001193125-24-008593-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}